Cloe PK facilitates drug discovery and agrochemical industries’ scientists to use ADME and physicochemical data to predict human and rodent pharmacokinetics.
The prediction allows drugs to be ranked and prioritised according their pharmacokinetic profile, without the need of in vivo studies.
The enhancements were made using a large in vivo dataset for building and testing the improvements to the model.
Cyprotex CSO Katya Tsaioun said the company continues to refine the Cloe PK software and this latest enhancement increases the model’s reliability and usability.